KEYTRUDA® (Pembrolizumab)

The FDA on February 15, 2019 approved KEYTRUDA® for the adjuvant treatment of patients with Melanoma with involvement of lymph node(s) following complete resection. KEYTRUDA® is a product of Merck & Co., Inc.